Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A04302 | Pages: NA | Charts: NA | Tables: NA |
Veterinary pain management is a crucial part of veterinary therapeutics. Pain not addressed appropriately in animals leads to delayed healing and exaggerated stress in already sick animals. Pain in animals could be due to surgeries, arthritis, and cancer that is accompanied with loss of appetite, aggression, and reduced activity. This could hinder the productivity of farm and pet animals. Ongoing research on lowering chronic pain in animals has made multiple options available to treat various causes of pain in animals that include pain medications, physical rehabilitation, acupuncture, laser therapy, and therapeutic massage.
The global veterinary pain management market has been witnessing significant growth, due to increase in adoption of pets as companions that increases the need of preventive treatments, medicines, and healthcare facilities for animals. Moreover, rise in need to maintain animal health and welfare in the developing countries and increase in adoption of pet insurance across the globe drive the growth of the market. In addition, increase in prevalence of animal diseases causing pain and inflammation fuels the market growth. However, lack of awareness towards serious disease conditions in companion animals restrains the growth of the market. On the contrary, increase in popularity of nonconventional and non-pharmaceutical treatment techniques and untapped emerging markets are anticipated to provide potential growth opportunity for the market.
The global veterinary pain management market is segmented on the basis of product, application, distribution channel, and region. By product, the market is differentiated into drugs and devices. Based on application, it is categorized into postoperative, cancer, arthritis, and others. Depending on distribution channel, it is divided into hospitals & clinics and pharmacy. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia pacific (Japan, China, Singapore, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players of operating in the market are Bayer AG, Boehringer Ingelheim International GmbH., Merck & Co., Inc., The Chanelle Group, Norbrook Laboratories Limited, Eli Lilly and Company, Inc., Dechra Pharmaceuticals PLC., Ceva Sante Animale, IDEXX Laboratories, Inc., and Zoetis.
Key Benefits
Key Market Segments
Key Market Players